Infectious gastroenteritis
Acute infectious diarrhoea with or without vomiting, managed by prioritising hydration and sepsis assessment, testing selectively, avoiding harmful antibiotics in STEC, and controlling transmission and public-health risk.
In a nutshell
Infectious gastroenteritis usually causes acute diarrhoea with or without vomiting and is managed supportively. First assess dehydration, perfusion, sepsis and an acute abdomen; use oral rehydration when possible, test stool selectively, avoid antibiotics and antimotility drugs in suspected STEC, and involve UKHSA for notifiable infections or outbreaks.
Classic presentation
Sudden diarrhoea with vomiting, abdominal cramps and sometimes fever after food, travel or sick contact. Watery diarrhoea with prominent vomiting suggests viral illness, while fever, severe pain, blood or mucus suggests inflammatory or invasive disease and changes the testing and escalation threshold.
Key points
- Dehydration, acute kidney injury and sepsis are the immediate threats; assess perfusion and urine output before focusing on the organism.
- Oral rehydration solution and continued age-appropriate feeding are first-line when oral intake is possible; use monitored intravenous fluids for shock, severe dehydration or failure of oral therapy.
- Most uncomplicated gastroenteritis does not need antibiotics or stool testing.
- Send stool microbiology for bloody or persistent diarrhoea, systemic illness, high-risk hosts, relevant travel or healthcare exposure, suspected outbreak or public-health request.
- Avoid antibiotics and antimotility agents when Shiga-toxin-producing E. coli is suspected because of haemolytic uraemic syndrome risk.
- Reduced urine output, pallor, bruising, oedema or neurological change after diarrhoea should trigger assessment for HUS.
- Wash hands with soap and water, clean contaminated surfaces and exclude from work, school or nursery until 48 hours after the last episode; follow longer organism-specific rules where required.
- Notify or discuss notifiable organisms, STEC, clusters and outbreaks with the current UKHSA pathway.
First-line investigation
Clinical hydration and sepsis assessment; send selective stool microbiology for bloody, persistent, systemic, high-risk, travel-related or outbreak-associated illness rather than testing every self-limiting case.
Management
Assess perfusion, sepsis and the abdomen
Rehydrate and provide supportive care
Test selectively and treat the cause
Stop transmission
Escalate STEC, HUS and outbreaks
Exam traps
- Do not give antibiotics or antimotility agents reflexively in suspected STEC; HUS is the key complication.
- Blood in stool, severe pain or sepsis is not a routine viral-gastroenteritis presentation and needs investigation and escalation.
- A stool pathogen result does not remove the need to assess hydration, renal function and alternative diagnoses.
- Recent antibiotics or healthcare exposure should prompt consideration of C. difficile, with its own testing pathway.
- Alcohol gel alone is not a substitute for soap-and-water handwashing in outbreaks where norovirus or other enteric infection is suspected.
- Do not miss an acute abdomen, diabetic ketoacidosis, inflammatory bowel disease or medication-related diarrhoea when the course is atypical.
Illustrations
Key sources
- UKHSA: Gastrointestinal infections: guidance for public health management (UK public-health guidance on prevention, transmission, exclusion periods, stool sampling, notifiable infection and risk-setting management)Published 31 Jan 2020
- NHS: Diarrhoea and vomiting (NHS advice on fluid replacement, expected duration, exclusion, infection-control measures and urgent red flags; next review due December 2026)Updated 21 Dec 2023
- NICE CG84: Diarrhoea and vomiting caused by gastroenteritis in under 5s (Current NICE clinical guidance for paediatric dehydration assessment, oral rehydration, intravenous fluids and selective antibiotic treatment)Published 22 Apr 2009
- NICE NG29: Intravenous fluid therapy in adults in hospital (Assessment, prescription, monitoring and reassessment principles for intravenous fluids and resuscitation in adults)
- UKHSA: Shiga toxin-producing Escherichia coli: public health management (Operational guidance for STEC O157 and non-O157 cases, including public-health follow-up, exclusion, HUS risk and local response)Updated 11 Jan 2023
- UKHSA: Notifiable organisms and how to report them (Current laboratory reporting guidance under the amended Health Protection Notification Regulations, including Salmonella and Shigella)Updated 11 Aug 2025
- UKHSA: Communicable disease outbreak management guidance (Current UK outbreak-management framework for health protection teams and partner agencies)Updated 2 Sept 2025
- NICE NG199: Clostridioides difficile infection: antimicrobial prescribing (Current NICE pathway for C. difficile testing context, antimicrobial exposure, treatment and specialist escalation when post-antibiotic diarrhoea raises this differential)Published 23 Jul 2021
This page is exam revision material, not medical advice, and must not be used for patient care. Always check drug doses against the BNF and current guidance. Full disclaimer.

